Diabetes Management Technology
Connected devices and apps managing diabetes care.
Market snapshot
These figures describe Diabetes & Metabolic Devices (4.8.3), the segment that Diabetes Management Technology sits within. They are not figures for Diabetes Management Technology on its own.
Within electromedical and instrument manufacturing (NAICS 334510/339112); the Census Bureau does not split out diabetes devices, so the segment is not separately sized.
Business model & economics
Revenue model
Devices plus high-margin recurring sensors and supplies
Key economics
- Recurring revenue
- High
- EBITDA margin
- Strong
- Capex intensity
- High
recurring CGM sensors and pump supplies
recurring-consumable economics
Characteristics
- Among the fastest-growing medtech categories.
- CGM adoption expanding into type 2 and wellness.
- Recurring sensor-and-supply razor-and-blade model.
Geographic concentration
Diabetes and metabolic-device manufacturing clusters in the major medtech hubs of Minnesota, Massachusetts, Utah, and California, home to the sector's leading device makers.
U.S. Census Bureau, 2022 Statistics of U.S. Businesses (firms by state), NAICS 334510/339112. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- Diabetes-device strategics
- Diversified medtech platforms
- VC-backed innovators
What’s driving deals
- CGM and automated-insulin-delivery growth.
- Expansion into type 2 and metabolic wellness.
- Recurring-consumable economics.
Find Diabetes Management Technology acquisition targets
Search Acquisera’s index for companies classified under Diabetes Management Technology (4.8.3.3) and build a targeted deal pipeline.
Search companies